Euro Ewing 2012
The American Ewing sarcoma regimen beat the European one in a head-to-head trial, unifying practice.
3-year EFS 67% vs 61% favouring VDC/IE (HR 0.71); OS HR 0.62; less toxicity and shorter duration. VDC/IE is now the international standard (JCO 2023).
Setting
Newly diagnosed Ewing sarcoma: VDC/IE (US-style) vs VIDE/VAI (European) induction/consolidation
Phase
Phase 3
Sponsor
University of Birmingham / EuroEwing consortium
Registry
Headline result
EFS HR 0.71; OS HR 0.62 favouring VDC/IE.
Reported
2020
Enrolled
640
In plain words
What these results mean for people, not percentages
Event-free survival at 3 yearsprimarysurrogate endpoint
- 67 vs 61 out of 100 free of a major event at 3 years with VDC/IE compared with VIDE; 6 more per 100.
- Roughly one extra person helped for every 17 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 29 percent lower chance of the event at any given time (hazard ratio 0.71, likely range 0.55 to 0.92).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed Ewing sarcoma: VDC/IE (US-style) vs VIDE/VAI (European) induction/consolidation. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.